TechVision Fonds — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
PL BioScience develops human platelet-based cell culture media that promote cell growth, used in biotechnology research and cell culture applications.
BiotechNew Materials
Dr. Hatim Hemeda(Founder & CEO)
Co-investorsAvant BioChemelot VenturesBetter Ventures Central LlcBrightlands Venture PartnersSeed Fonds Aachen
Vivalyx develops organ revitalization technology aimed at improving organ vitality for transplantation.
BiotechHealthtechMedical DevicesAachen, DE
Benedict Doorschodt(Founder)in
Co-investorsChemelot VenturesGOOSE CapitalNextGen VenturesSeed Fonds AachenTechVision FundBessemer Venture Partners+2 more
Zenflow develops a minimally invasive medical device, the Spring implant, to relieve urinary obstruction caused by benign prostatic hyperplasia (BPH) in men.
HardwareHealthtechMedical DevicesSan Francisco, US
Shreya Mehta(CTO)inNick Damiano(CEO)inJohn Beck(Executive Officer)in
BoardBryan Kim(Director)Robert Weisskoff(Director)inBlayne Roeder(Director)
Co-investorsAstiaCloudStone CapitalDorm RoomF-Prime CapitalShangBay Capital LLCY Combinator+15 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.



.png)









